Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The news that will arrive in cascade:
- Detected movie release (April 27th)
Anytime after
- Public results for the clinical trials, if not already in the film
- FDA filling, if not already in the film
- Cyrcadia buys LLBO US Patents
- Major investor or partnership
- Health insurance company agreements
- Filling for International patents
- CE filling
- Launch of the US pilot commercialization
- FDA clearance
- CE clearance
- Pharmaceutical distributors agreements
- Commercial launch in Asia
- Commercial launch in the US
- Commercial launch in Europe
Most of this is expected to happen during this year!
April 28th will be the starting of a new reality for LLBO/Cyrcadia because we will have in our hands the most powerful communication tool imaginable: a Cisco-funded film that shows how this technology will radically change the detection of breast cancer around the world thanks to a wearable and the IoT (Internet of Things)
The media will go crazy to echo the news!
This will automatically double whatever the price when they make public the press release with the word CISCO in it.
At the moment few people know about the release of the movie next Thursday 27th after the market closes.
No dilution in the last 8 years!
Do your DD people.
I agree that maybe we will never see $0.50
But LLBO at $0.05-$0.10 seems perfectly possible for me, after approval.
I also think we could see $0.01 before next Thursday.
IMO
This would mean a $1,500,000,000 valuation for LLBO
You never know with tech stocks but I'm more confortable with a $0.05-$0.10 price range for a $150,000,000-$300,000,000 valuation before the end of the year. From there everything is possible if they do things right.
They have a huge market opportunity in the US, Europe and Asia and a multi-leve business model: sale of products (iTbra) + data analysis with a monthly or annual subscription. Think about it: ANY woman in the world could buy this for an affordable price or have it included within their health insurance plan!
THIS IS HUGE!
3,749,510,222 women in the World (2017)
1,000,000 breast cancer deaths all over the World in 2016 (estimate)
----
164.148,516 women in the US (2016)
292,130 new breast cancers in the US in 2015
40,290 women died of breast cancer in the US in 2015
Remember that when LLBO patents are transferred to Cyrcadia, LLBO could get around 50% of Cyrcadia stock according to their current agreements, compared to the 33% they have now.
LLBO has the US patents.
In the coming months Cyrcadia will apply for world patents.
No competition.
This product has required +20 years of research.
They have connections with CISCO and Flextronics.
Can save the government and insurance companies billions of dollars in the US alone.
It is also perfect for poor countries because it is cheap.
They can control all the market!
IMO this is the last chance to get a cheap entry price!!!!
When this will be in the news all over the world, it will not drop below $0.01 anymore.
You should see $0.0025-$0.0050 before April 27th.
I can't believe we already have a product ready for FDA approval and commercialization. But I can tell you that if this is the case and we get that approval, we will be trending topic in the media all over the world.
Thousands of women will safe their life thanks to this product.
The potential market is huge and very soon we will see this reflected in LLBO's price!
Now we know that CISCO has given the OK!
https://newsroom.cisco.com/feature-content?type=webcontent&articleId=1839363&CAMPAIGN=Corporate%20Communications&Country_Site=GL&POSITION=Social+Media&REFERRING_SITE=Twitter&CREATIVE=Cisco++
Awaiting the joint press release from CISCO, Cyrcadia and LLBO announcing the launch of this documentary. The perfect moment would be next Monday 24th to enter the media agendas. When this happens, if it happens, IMO the price will start to increase progressively, and we will not see the $0.0010-$0.0025 for quite some time or maybe never again. Until then LLBO followers have a unique opportunity to buy at these prices. Then, as always happens, people will start buying at much higher prices for not having the courage to do it now. I hope they have reserved $1K of the $1M budget for communication.
DD: Latest articles and upcoming Cyrcadia events
This is for real! Things are accelerating.
Assumptions (IMO):
- Cisco would not have authorized the release of the documentary if the technology had not proved its effectiveness in the clinical study.
- Cyrcadia would not have authorized the release of the documentary if its clinical study was not already finished because it would be illegal.
- Once the Detected documentary is out, media awareness will increase exponentially and the price of LLBO should increase in equal measure.
- The documentary marks the beginning of a communication campaign in which the outcome of the study and the request for approval by the FDA will be the culminating point.
ROB ROYEA UPCOMING EVENTS (NEXT 2 MONTHS)
27 June 2017 | Rob Royea speaker at Clinical Trials - Mobile Innovations Summit
Leverage Mobile Tools in Clinical Trials to Improve the Patient Experience
NEW YORK ACADEMY OF SCIENCES
http://panagorapharma.com/clinicaldata/
18 June 2017 | Rob Royea speaker at AIS Healthy Ageing
Hong Kong Convention and Exhibition Centre
https://apacinnosummit.hkstp.org/en/ais-healthy-ageing/
May 18, 2017 | Rob Royea speaker at The World Precision Medicine Congress
https://www.personalizemymedicine.com/personalized-medicine-news/
May 18, 2017 | Rob Royea speaker at FREE NHS HEALTHCARE TRACK
DAY 2: THURSDAY 18TH MAY 2017 14:00-19:30
http://www.terrapinn.com/conference/world-precision-medicine-congress/Free-NHS-track.stm
Ma7 17, 2017 | Rob Royea speaker at CordBlood WorldEurope 2017
Business Design Center, London
http://www.terrapinn.com/conference/cord-blood-world-europe/speakers.stm
CYRCADIA QUOTED IN THE LAST 3 MONTHS
April 12, 2017 | How can AI enhance Cancer treatment and detection?
http://data-speaks.luca-d3.com/2017/04/how-can-ai-enhance-cancer-treatment-and_62.html
April 7, 2017 | Tecnología para la salud: estos ‘wearables’ te ayudarán a llevar una vida sana
https://www.cookingideas.es/wearable-salud-20170407.html
April 6, 2017 | Machines that learn to do, and do to learn: What is artificial intelligence?
http://bruegel.org/2017/04/machines-that-learn-to-do-and-do-to-learn-what-is-artificial-intelligence/
Apr 03, 2017 | Deep Learning in Drug Discovery and Diagnostics, 2017 - 2035
http://www.prnewswire.com/news-releases/deep-learning-in-drug-discovery-and-diagnostics-2017---2035-300433645.html
March 28, 2017 | How Remote Patient Monitoring and Wearables Will Transform Healthcare
http://www.jabil.com/blog/how-remote-patient-monitoring-and-wearables-will-transform-healthcare/
March 23, 2017 | Brilliance@Work: Blue Sky Innovator John Silva
https://starrybluebrilliance.com/2017/03/23/brilliancework-blue-sky-innovator-john-silva/
March 17, 2017 | How Technology Will Take Fitness to a New Level
https://www.mymetabolicmeals.com/technology-will-take-fitness-new-level/
March 16, 2017 | Are wearables the future of healthcare? | Tech City News
http://techcitynews.com/2017/03/16/are-wearables-the-future-of-healthcare/
March 2017 | Global Artificial Intelligence in Medicine Market to Grow at a Tremendously CAGR of 44.8% and Market Value of USD 6,000 Million by 2022
http://www.medgadget.com/2017/03/global-artificial-intelligence-in-medicine-market-to-grow-at-a-tremendously-cagr-of-44-8-and-market-value-of-usd-6000-million-by-2022.html
March 2017 | Global Artificial Intelligence in Medicine Market – Growth, Trends, and Forecasts (2016 - 2021)
https://www.mordorintelligence.com/industry-reports/artificial-intelligence-in-medicine-market
February 3, 2017 | From Virtual Nurses To Drug Discovery: 106 Artificial Intelligence Startups In Healthcare
https://www.cbinsights.com/blog/artificial-intelligence-startups-healthcare/
January 31, 2017 | Allianz Asia Lab: Cyrcadia
https://allianzasialab.com/AZAP/
https://allianzasialab.com/AZAP/Earlybreastcancerdetection
January 27, 2017 | Top 11 Tech Startups Creating Solutions for Treating or Curing Cancer in 2017
https://www.techflier.com/2017/01/27/top-11-tech-startups-creating-solutions-for-treating-or-curing-cancer/
January 16, 2017 | ITbra intelligent bra to monitor breast cancer in real time
iTbra???? ???????? (Chinese)
http://www.totiot.com/65338.html
January 5, 2017 | Cycadia Health: Use iTBra smart underwear to help you prevent "wild killer"
Cycadia Health:?iTBra????????“????” (Chinese)
http://med.sina.com/article_detail_100_2_18041.html
If you are so concerned about a reverse split, that didn't happened in the last 8 years, sell after the Detected documentary is released.
A reverse split is not negative in itself if it is not accompanied by the issuance of new shares, something that has not happened either in the last 8 years.
LLBO does not execute anything from a business point of view, so it does not need to make a reverse split nor the issuance of new shares.
Obviously Cyrcadia will one day be interested that both companies are merged, but I do not se them going public anytime soon. That should happen in a major market and not in OTC/Pink.
I see more likely that Cyrcadia/LLBO will be part of an acquisition by a much larger company once we are aware that the new product works and has been approved by the FDA.
All this does not worry me now if the price of LLBO is by then at $0.05.
>>> And please, delete all your repeated messages, if you know how to do it! We understand your point with a single one.
8 year without a single reverse split or relevant share increase
It will be enough if they show a finished clinical trial for a product that correctly detects breast cancer.
The key is to correctly document the cancer screening process with a single patient, and to show how that patient has been able to do that test from home. And how the data has been received and treated by the detection system and then transferred to her doctor. According to the data obtained, the doctor will be able to indicate the need, or not, for the patient to have a mammogram, with the consequent savings compared to the current protocol. And in any case it will be able to detect breast cancer in the early stages, saving the lives of millions of women who are now dying like flies.
TV journalist will be able to explain this in only 60 seconds if the trial is a success.
Screening times for the Detected movie:
- Thu, Apr 27 7:30 PM
- Sun, Apr 30 12:30 PM
Only two weeks to go.
We may be facing the last chance to buy at these prices!
Sources:
http://prod1.agileticketing.net/websales/pages/list.aspx?epguid=48d2af79-ea7d-4e1e-a0a7-5ec3d6c8ceef&alpha=d&
http://prod1.agileticketing.net/websales/pages/info.aspx?evtinfo=118600~a237b910-f867-48f1-bae1-19794b59b1f0&epguid=48d2af79-ea7d-4e1e-a0a7-5ec3d6c8ceef&
¿Qué broker estás usando en España?
A mi iBroker/Clicktrade me ha bloqueado la compra de LLBO y el resto de OTC.
Something sounds very bad to me:
How is it possible that if LLBO is the maximum shareholder of Cyrcadia, LLBO investors do not have any information on what is happening. Because that means that we, the investors of LLBO are the majority investor of Cyrcadia. And Jim Holmes is our man on the board.
LLBO's latest press release is from June 2016, almost a year ago.
Jim Holmes does not care about LLBO's investors at all, otherwise he would have informed us about all the news that direct investors in Cyrcadia have received in the latest shareholding meeting.
Why Jim Holmes treats LLBO investors as trash?
Why does Jim Holmes hide information to LLBO's investors?
That is also illegal. Don't you think?
I agree with you this has a HUGE potential.
We could easily see $0.01 with the end of a positive clinical trial and much more with approval.
I am only worried about the capacity of the current Cyrcadia team to deliver.
The best product of the world is worthless without a proper team to bring it to market.
I cross my fingers ;)
No problem. I will be happy to acknowledge my mistake if you are right because that will mean that I will be making money. But based on my previous experience with this company, let me doubt about it.
I have been an investor in LLBO for 8 years, and I'm still waiting.
I assure you that I know what I'm talking about when I refer to keeping dreams.
I also think it is not logical to present the documentary without positive news, but we have to see how positive they are. Having positive results doesn't mean the clinical trial is finished, and we are still very far from FDA approval.
Don't worry, if the documentary shows positive news we will see $0.004 in minutes and you will be able to sell.
Let everyone believe in what they want, but let's keep a discussion based on facts and proper diu diligence. Not based on dreams!
I'm the first one who wants to start the party, and I am not selling before we see the $0.05, just to keep into perspective how much I think this is a disruptive technology.
Making people dream does not make dreams more real.
This documentary will only serve to keep the dreamers, if not accompanied by a press release from the company that indicates the completion of the clinical trial with positive results.
At the moment this "incredible" documentary is not generating any buyer appetite.
In less than 3 weeks we will have the answer.
I also hope we have positive news, but I refuse to continue dreaming.
Maybe the content is not what we expect.
If the documentary is limited to showing a technology with potential it will not provide any price increase, and even worse, the price will fall again to $0.000x.
If on the contrary the documentary shows a technology ready for commercialization and with positive clinical results the price can easily surpass $ 0.004.
This documentary is positive news, but does not represent any relevant fact from a business point of view. What we all expect is the following:
- Confirmation of completion of clinical trial.
- Confirmation that the clinical trial data are positive.
- Confirmation of initiation of the application for FDA approval.
These are the relevant news that we are waiting for. We will see if we listen about that before the summer, or if everything is delayed again for another 6 to 12 months, as it has been happening in the last years.
I hope the best but I do not believe anything else until I see it.
I have heard too many lies from LLBO and Cyrcadia in recent years.
The trial may still take months to complete, but Cyrcadia has the urgent need to raise money from investors so the whole project does not end in failure. Otherwise, they will not be able to buy the patents to LLBO before the end of June.
This is the last opportunity they have to raise the investment needed to get this product to market. If they do not get it after this documentary is launched, they will have to negotiate a new agreement with LLBO that surely will not be so favorable.
The key is the ownership of the patents. If Cyrcadia does not get the patents, they will not have new investors, and without new investors they can't execute their production, marketing and commercial plan.
IMO if we don't get news before the end of June will be very bad for all of us.
Detected also in Cannes (France) May 17th
http://sub.festival-cannes.fr/SfcCatalogue/MovieDetail/7b109d37-3542-491c-993d-c74503e1a333
No one in their right mind would release a film sponsored by CISCO if the results of the clinical trial were not as expected.
I hope this time they make a correct communication campaign.
This is the perfect opportunity for all the media and doctors to know this technology, and to convince investors that they can multiply their investment by 10 before the end of the year, and by 100 in the next 5 years.
Excellent news for all LLBO investors.
Let the party begin!!!!
Yes we have relevant information: As of today Cyrcadia has not raised the 1.5 million dollar needed to exercise its right to buy the LLBO patents before June 30th 2017.
Now, the questions are:
- Why such an "incredible" product is not able to raise such an small amount of money?
- Why, after nearly 2 years of clinical trials in two hospitals, they have not been able to enroll the 173 needed patients?
- Why don't we have up-to-date data on the number of patients enrolled in the trial and the "new" estimated completion date?
- Why LLBO does not inform its investors and keeps, for itself, the information transmitted to them by Cyrcadia?
- Why LLBO's stock price does not even have a fraction of the value it should have if the data we have it's true?
Get ready for, at least, another year without news!
ARTICLE: Wearable device uses predictive modeling for early breast cancer detection
Source: https://www.dotmed.com/news/story/30230
April 11, 2016
by John W. Mitchell , Senior Correspondent
The iTBra — a wearable device that relies on a woman's circadian rhythm to detect breast cancer lesions earlier and reduce false positives — is showing promise as researchers accumulate more data.
The developer, Cyrcadia Health, has announced it will expand the field trials for the smartphone enabled technology to a second site at The Stefanie Spielman Comprehensive Cancer site at The Ohio State University. The company is also working on a third trail expansion internationally with the Medicine X group at Stanford University.
“We typically think of medicine being performed in a clinical setting,” Rob Royea, CEO and chairman at Cyrcadia Health, told HCB News. “But our device flips that model on its head to empower the individual. We can track changes over time to find disease earlier, reduce costs and get better outcomes for women who develop breast cancer.”
He said that current testing is designed to show how the device could reduce false positives, which account for 70 percent of breast biopsies and contribute $1.6 billion in unnecessary health care spending annually.
The iTBra works by attaching a patch to each breast, similar to an EKG Holter monitor.
The device, which fits comfortably under a bra, measures and stores the body’s circadian rhythms generated by natural light changes to a woman’s genetic make-up. According to Royea, these measurements can be collected in from two to 24 hours.
This data is then uploaded to a global cancer library site where a proprietary set of predictive algorithms analyze the information for abnormalities to indicate the presence of early breast cancer lesions.
“The analysis is fully automated with no human intervention,” said Royea. “A woman can wear the device while shopping or taking care of her children. The predictive analysis is sent to her doctor who can then follow-up with the patient.”
According to Royea, a former Johnson & Johnson and Siemens executive, there are other advantages to the iTBra. Early tests show promise in determining the difference between tissue-infused and encapsulated cancers in the milk duct of the breast. This diagnosis currently requires a biopsy — which can transfer active cancer cells to surrounding tissue — to confirm.
The device may also reduce a woman’s exposure to mammography, as well as the radiation and compression discomfort that accompany those exams, said Royea. Cyrcadia has been invited to help screen women internationally who refuse to expose their breasts to physician or hospital staff for religious reasons.
“It’s quite exciting to have The Ohio State join the current study,” said Royea. “The clinical team there had experience with an earlier version of the device that did not have the scalability of the current device.”
Trials expanding in parallel to FDA 510(k) file
March 31, 2016 News release:
http://www.otcmarkets.com/stock/LLBO/news/Lifeline-Biotechnologies-Announces-a-Cyrcadia-Milestone-and-2016-Expectations?id=128543&b=y
Most relevant information in the news release
-----------------------------------------------
1. This is the confirmation we all have been waiting since July last year:
[Cyrcadia Health announced the extension of its clinical trial for early breast cancer detection to The Stefanie Spielman Comprehensive Breast Center at The Ohio State University, in Columbus, Ohio. The trial, which began in 2015 at El Camino Hospital, in Mountain View, California, will continue at both locations to reach enrollment of 173 patients focused on breast cancer health screening.]
2. This is the confirmation from a third party that the clinical trials are advancing OK:
[Dr. Shyamali Singhal, founder of the El Camino Hospital Cancer Center. “The trial at El Camino Hospital opened with strong interest from the patient population and the early results are indeed promising. We look forward to further involvement with the Cyrcadia study here at El Camino Hospital.”]
3. This is the confirmation that Cyrcadia should file for FDA approval during the current clinical trials to win time:
[Cyrcadia expects to file its notification for 510(k) clearance with the FDA parallel with the current 173 patient trial.]
4. This is the confirmation that 2016 is a big year for all of us:
[Year 2016 expectations are that the clinical trials will be completed, the regulatory filings will be achieved which is intended to lead to clearance by the FDA of the 510(k) application and CE Mark authoritative body]
-----------------------------------------------
My own opinion is that things are going on as scheduled and that there is no need to worry until the end of the trials. But remember: invest only the money you can loose and that you don't need for living.
DISCLOSURE: I am from Europe and invested since October 2009. I have been adding to my position multiple times in 2015 and 2016.
IMPORTANT FILINGS
Mar 30, 2016 - Management Discussion and Analysis - Annual Disclosure Statement Dec 31, 2015 - http://www.otcmarkets.com/financialReportViewer?symbol=LLBO&id=152208
92,200,000 new shares issued during 2015
----------------------
Mar 30, 2016 - Annual Report - Dec 31, 2015 - http://www.otcmarkets.com/financialReportViewer?symbol=LLBO&id=152206
This is the most important part in the Anual report: Note 12 - Page 14
If the option is exercise by Cyrcadia before the end of July 2017 (15 months from March 5, 2016), Lifeline could get 50% of Cyrcadia shares instead of the current 33%, but will loose its patents and royalties.
But of course this percentage could go down if the required $1,200,000 in additional capital is raised, which will dilute the existing shareholders of Cyrcadia